Download PDF

1. Company Snapshot

1.a. Company Description

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States.Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.The company was formerly known as Harmony Biosciences II, Inc.


and changed its name to Harmony Biosciences Holdings, Inc.in February 2020.Harmony Biosciences Holdings, Inc.


was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Show Full description

1.b. Last Insights on HRMY

Harmony Biosciences Holdings, Inc.'s recent performance was negatively impacted by its Q2 earnings miss, with quarterly earnings of $0.68 per share, falling short of the Zacks Consensus Estimate of $0.78 per share. The company's revenue growth, although 16% year-over-year, was not enough to offset concerns. Additionally, the company's upcoming topline data from its phase 3 registrational clinical trial of ZYN002 in Fragile X syndrome, expected in Q3 2025, has not yet been released, creating uncertainty. (Source: Zacks)

1.c. Company Highlights

2. Harmony Biosciences' Strong Q4 2025 Results Position Company for Blockbuster Status

Harmony Biosciences reported net revenues of $243.8 million for the fourth quarter of 2025, representing a 21% growth from the same period last year and the company's highest quarterly revenues to date. The total operating expenses for the quarter were $136.7 million. The company's earnings per share (EPS) came in at $0.38, missing analyst estimates of $0.84. Despite the EPS miss, the company's strong revenue growth and robust pipeline position it for blockbuster status in 2026, with guided WAKIX net revenue of $1 billion to $1.04 billion.

Publication Date: Mar -07

📋 Highlights
  • Q4 2025 Revenue Growth:: Achieved $243.8M net product revenue (+21% YoY from $201.3M in Q4 2024), marking the highest quarterly revenue in company history.
  • WAKIX Blockbuster Guidance:: Targeting $1B–$1.04B in net revenue for 2026, reflecting its commercial strength and positioning as a blockbuster in narcolepsy treatment.
  • Phase III Pipeline Expansion:: Five ongoing registrational trials across five distinct CNS indications, including pediatric cataplexy and new formulations of pitolisant with IP protection until 2042.
  • Financial Strength:: Ended Q4 2025 with $882.5M in cash, cash equivalents, and investments, ensuring robust funding for pipeline development and commercial growth.
  • Commercial Team Expansion:: Field-based teams expanded by ~20% in 2026, coupled with a new patient portal to enhance access, aiming to drive WAKIX adoption and market share.

Commercial Performance

The company's commercial performance was driven by continued strong demand for WAKIX, with Adam Zaeske, Chief Commercial Officer, stating that 2025 marked a year of unprecedented and record-setting performance for WAKIX. The company is expanding its field-based teams by almost 20% across its field sales, field reimbursement, and remote sales teams to support the growing demand. As Zaeske noted, "We are launching a new online portal to enable easier and faster access for patients."

Pipeline Advancements

Harmony Biosciences' robust late-stage pipeline continues to advance, with 5 ongoing Phase III registrational trials towards 5 distinct CNS indications. The company is also exploring broader CNS indications with a new formulation of pitolisant, supported by newly licensed IP with patent protection until 2042. Kumar Budur, Chief Medical and Scientific Officer, highlighted the progress in the orexin-2 receptor agonist program, with Phase I data expected in mid-2026.

Financial Position

The company ended the fourth quarter with $882.5 million in cash, cash equivalents, and investments, providing it with the financial flexibility to execute on its growth strategy. With a P/E Ratio of 10.29 and an EV/EBITDA of 4.48, the company's valuation multiples suggest a reasonable price for its earnings and cash flow generation. Additionally, the company's Return on Equity (ROE) of 19.84% and Return on Invested Capital (ROIC) of 13.9% indicate a strong ability to generate returns for shareholders.

Outlook

Harmony Biosciences is well-positioned for blockbuster status in 2026, driven by its strong commercial performance and advancing pipeline. Analysts estimate next year's revenue growth at 12.5%, suggesting a continued upward trajectory for the company. With its robust financial position and diversified pipeline, Harmony Biosciences is poised for long-term success.

3. NewsRoom

Card image cap

Harmony Biosciences to Participate in Upcoming Investor Conferences

Mar -04

Source: businesswire.com

Card image cap

Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript

Feb -24

Source: seekingalpha.com

Card image cap

Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates

Feb -24

Source: zacks.com

Card image cap

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

Feb -24

Source: businesswire.com

Card image cap

4 Value Stocks to Buy Now Amid AI-Driven Market Volatility

Feb -18

Source:

Card image cap

Top 5 Bargain P/B Stocks Investors Should Watch Now

Feb -18

Source: zacks.com

Card image cap

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

Feb -17

Source: businesswire.com

Card image cap

3 Reasons Why Growth Investors Shouldn't Overlook Harmony Biosciences (HRMY)

Feb -16

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Pharmaceutical

Expected Growth: 8.5%

Harmony Biosciences Holdings, Inc.'s 8.5% growth in pharmaceuticals is driven by increasing demand for rare disease treatments, strong pipeline of novel therapies, and strategic partnerships. Additionally, growing awareness of sleep disorders and increasing adoption of Wakix, its flagship product, contribute to the segment's growth.

7. Detailed Products

Wakix

A medication used to treat excessive daytime sleepiness (EDS) in adult patients with narcolepsy

Pitolisant

A medication used to treat excessive daytime sleepiness (EDS) and cataplexy in adult patients with narcolepsy

Xyrem

A medication used to treat cataplexy and excessive daytime sleepiness in adult patients with narcolepsy

8. Harmony Biosciences Holdings, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Harmony Biosciences Holdings, Inc. operates in a niche market with limited substitutes, reducing the threat of substitutes.

Bargaining Power Of Customers

Harmony Biosciences Holdings, Inc. has a diverse customer base, reducing the bargaining power of individual customers.

Bargaining Power Of Suppliers

Harmony Biosciences Holdings, Inc. relies on a few key suppliers, giving them some bargaining power, but the company's size and scale mitigate this threat.

Threat Of New Entrants

Harmony Biosciences Holdings, Inc. operates in a highly regulated industry with significant barriers to entry, reducing the threat of new entrants.

Intensity Of Rivalry

Harmony Biosciences Holdings, Inc. operates in a competitive industry with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 29.30%
Debt Cost 7.69%
Equity Weight 70.70%
Equity Cost 7.69%
WACC 7.69%
Leverage 41.45%

11. Quality Control: Harmony Biosciences Holdings, Inc. passed 8 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Harmony Biosciences

A-Score: 5.7/10

Value: 6.4

Growth: 9.4

Quality: 9.0

Yield: 0.0

Momentum: 5.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Puma Biotechnology

A-Score: 5.4/10

Value: 7.3

Growth: 6.0

Quality: 8.6

Yield: 0.0

Momentum: 9.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
iTeos Therapeutics

A-Score: 4.9/10

Value: 7.8

Growth: 3.6

Quality: 4.4

Yield: 0.0

Momentum: 8.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
CytomX Therapeutics

A-Score: 4.9/10

Value: 3.2

Growth: 6.2

Quality: 9.4

Yield: 0.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Amylyx Pharmaceuticals

A-Score: 4.3/10

Value: 8.7

Growth: 3.6

Quality: 6.8

Yield: 0.0

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Akebia Therapeutics

A-Score: 2.8/10

Value: 4.4

Growth: 5.7

Quality: 3.9

Yield: 0.0

Momentum: 1.5

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

27.72$

Current Price

27.72$

Potential

-0.00%

Expected Cash-Flows